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Impaired autoregulation of the glomerular filtration rate in We have previously demonstrated that autoregulation
patients with nondiabetic nephropathies. of GFR is defective in type 1 and type 2 diabetic patients
Background. The ability of the kidney to maintain constancy with diabetic nephropathy [2, 3]. Furthermore, it hasof the glomerular filtration rate (GFR) over a wide range of
been shown that an initiation of antihypertensive treat-renal perfusion pressures is termed autoregulation. Defective
ment induces a faster initial and slower subsequent de-autoregulation of GFR has been demonstrated in diabetic ne-
phropathy. Whether this is also the case in patients with nondia- cline in GFR in hypertensive type 1 and type 2 diabetic
betic nephropathies is not known. patients with incipient or overt diabetic nephropathy
Methods. We investigated the effect of acute lowering of
[4–6], which may be due to a functional (hemodynamic)blood pressure (BP) on GFR in 16 (8 males and 8 females)
effect of antihypertensive treatment and/or changes inalbuminuric subjects suffering from different nondiabetic ne-
phropathies and in 14 (7 males and 7 females) controls matched autoregulation mechanisms in patients with diabetic ne-
with respect to sex, age, BP, and baseline GFR. The subjects phropathy [7, 8]. The same biphasic phenomenon has
received in random order an intravenous injection of either also been shown in patients with nondiabetic nephropa-clonidine (150 to 225 mg) or saline (0.154 mmol/liter) within
thies, but the autoregulation of GFR has not been evalu-two weeks. We measured GFR ([51Cr]-EDTA), albuminuria
ated [9, 10].(enzyme-linked immunosorbent assay; ELISA), and BP
(Takeda TM-2420). Elevated blood pressure (BP) is common in patients
Results. Clonidine induced similar reductions in mean arte- with nephropathy and may accelerate the injuries of the
rial BP 17 (2) versus 19 (2) mm Hg [mean (se)] in patients with glomerular capillaries because the protection against in-nephropathy and in controls, respectively. GFR diminished in
creased hydrostatic pressure and/or increased flow is di-average from 89 (6) to 82 (5) ml/min/1.73 m2 (P , 0.05), and
minished because of impaired autoregulation.albuminuria declined from a geometric mean of 1218 (antilog
se 1.3) mg/min to 925 (1.3) in the patients with nondiabetic Therefore, the aim of our case-control study was to
nephropathies (P , 0.05), whereas these variables remained investigate the effect of acute BP reduction on GFR in
unchanged in the control group. The mean difference between
albuminuric patients with nondiabetic nephropathies.changes in GFR (95% confidence interval) between the nondi-
abetic macroalbuminuric and control subjects was 6.1 (20.03
to 12.21) ml/min/1.73 m2 (P 5 0.051).
METHODSConclusion. Our study suggests that albuminuric patients
with nondiabetic nephropathies frequently suffer from im- We selected 16 nondiabetic subjects with albuminuria
paired autoregulation of GFR. (.300 mg/24 hr). A kidney biopsy had been performed in
15 of the 16 patients, showing different types of glomerulo-
nephritis (N 5 12), minimal change (N 5 1), focal glo-
The ability of the kidney to maintain constancy of merulosclerosis (N 5 1), and near normal structure (N 5 1)
glomerular filtration rate (GFR) over a wide range of (Table 1). Fourteen nondiabetic normoalbuminuric sub-
renal perfusion pressures is termed autoregulation [1]. jects who matched the patients with nephropathy in re-
spect to sex, age, and arterial BP level were studied as
a control group (Tables 1 and 2).Key words: albuminuria, renal perfusion pressure, glomerular filtration
rate, blood pressure, autoregulation. All subjects gave informed consent to participate in
the study. The study was approved by the local ethicsReceived for publication January 11, 1999
committee and was conducted according to the principlesand in revised form April 13, 1999
Accepted for publication May 18, 1999 expressed in the Declaration of Helsinki.
Three of the patients with albuminuria received anti- 1999 by the International Society of Nephrology
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Table 1. Clinical data of nondiabetic subjects with and without nephropathy
Time between kidney Duration
biopsy and examination of diseasea
Subjects Sex Age years years Diagnosis years
Patients with macroalbuminuria N (M/F) 5 8/8
1 M 33 0.5 GN, epimembranous 0.5
2 M 34 6 GN, unclassified 27
3 F 21 1 GN, proliferative 1.5
4 F 23 0.5 GN, proliferative 12
5 M 33 0.5 GN, unclassified 4
6 M 49 0.5 GN, epimembranous 0.5
7 F 59 1.5 Minimal change 3
8 M 50 0.5 Glomerulosclerosis 0.5
9 M 15 0.5 GN, proliferative 0.5
10 F 42 7 GN, proliferative 7
11 F 38 Not done 2
12 F 29 1 GN, proliferative 1
13 M 31 9 GN, proliferative 9
14 F 49 2 GN, proliferative 30
15 F 44 17 GN, proliferative 18
16 M 51 7 Near normal structure 9
Mean (sd) 38 (12)
Control subjects N (M/F) 5 7/7
1 F 35
2 M 35
3 M 32
4 M 32
5 F 36
6 F 25
7 F 33
8 M 50
9 M 30
10 M 45
11 F 66
12 F 32
13 F 60
14 M 35
Mean (sd) 39 (12)
Abbreviation GN is glomerulonephritis.
aTime between onset of albuminuria and examination.
hypertensive treatment before the study. One was by multiplying EDTA clearance by 1.10 [11]. The results
were standardized for 1.73 m2 body surface area usingtreated with b-blocker, one with bendroflumethiazid,
and one with spironlacton and nifedipine. None of the the patients surface area at the start of the study. The
mean coefficient of variation in GFR from day to daycontrols received antihypertensive treatment.
Patients treated with antihypertensive drugs stopped was 4%.
To correct for baseline/residual radioactivity, a venousthe antihypertensive treatment four weeks before the
first examination. blood sample was taken at each GFR determination
before the injection of 51Cr-EDTA.We performed a randomized single-blind case-control
study. The study was performed twice within two weeks, Patients rested supine during the entire investigation
and drank approximately 200 ml of tap water per hour.with the subjects receiving a slow intravenous injection
(10 min) of either clonidine (150 to 225 mg; Boehringer, BP and heart rate was measured with the Takeda
TM2420 device (A&D, Tokyo, Japan) using the rightIngelheim, Germany) or saline (0.154 mmol/liter) in ran-
dom order. arm, appropriate cuff sizes [25 3 12 cm (upper arm
circumference #35 cm) and 30 3 15 cm (upper armThe patients had their usual breakfast.
The GFR was measured in a four-hour period (9 a.m. circumference .35 cm)] at baseline after at least 10 min-
utes of rest in the supine position and every 10 minutesto 1 p.m.) after a single intravenous injection of 3.7 MBq
of Na 51Cr-labeled eidetic acid ([51Cr]-EDTA) by de- during the GFR measurements. The mean arterial BP
(MABP) was calculated as the diastolic BP plus onetermining the radioactivity in venous blood samples
taken at 180, 200, 220, and 240 minutes after the injection third of the pulse amplitude.
Urinary albumin excretion (UAE) during the four-[11, 12]. The small underestimation (10%) of 51Cr-EDTA
clearance versus clearance of inulin was corrected for hour period was determined by using an enzyme-linked
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Table 2. Arterial blood pressure (BP), glomerular filtration rate (GFR) and urinary albumin excretion (UAE) in nondiabetic subjects
with and without nephropathy
BPa mm Hg GFRa ml/min/1.73 m2 UAEb mg/min
Before After Before After Before After
Subjects clonidine clonidine clonidine clonidine clonidine clonidine
Patients with nephropathy
1 130/83 (6/3) 108/68 (4/6) 99 97 2961 1942
2 129/76 (5/5) 109/69 (8/5) 121 102 726 477
3 121/68 (4/6) 95/53 (3/3) 107 73 964 255
4 115/70 (5/4) 95/59 (7/4) 100 87 804 1052
5 108/70 (5/3) 100/69 (3/3) 82 79 1527 2004
6 140/87 (8/5) 121/78 (7/4) 75 71 1417 1595
7 121/78 (5/3) 88/59 (5/3) 74 79 203 152
8 156/95 (5/8) 129/84 (6/5) 69 62 9297 6749
9 122/77 (4/6) 108/68 (3/3) 137 132 4825 6976
10 155/96 (1/13) 118/84 (15/14) 40 48 888 758
11 127/85 (8/5) 104/71 (14/7) 115 99 693 756
12 118/78 (8/5) 94/66 (11/8) 88 92 1977 1064
13 171/109 (8/6) 127/89 (5/4) 95 79 322 250
14 110/74 (5/6) 96/63 (4/4) 85 78 682 374
15 133/93 (6/4) 104/79 (5/4) 66 68 681 351
16 164/108 (9/4) 118/87 (8/5) 69 58 3932 2537
133/84 (19/13) 107/72 (12/11) 89 (24) 81 (20) 1218 (1.3) 925 (1.3)
P , 0.01 P , 0.05 P , 0.05
Control subjects
1 118/82 (3/4) 99/71 (8/8) 101 105 7 7
2 139/88 (5/8) 103/65 (7/5) 93 90 10 5
3 112/67 (2/3) 101/64 (4/3) 98 97 7 7
4 109/75 (2/1) 78/52 (6/7) 98 98 6 7
5 133/89 (5/4) 104/76 (3/6) 92 89 5 6
6 147/108 (3/6) 130/93 (4/5) 113 105 28 17
7 129/88 (5/11) 110/75 (4/3) 88 92 3 4
8 181/114 (4/4) 146/97 (6/3) 79 75 6 7
9 152/99 (7/5) 127/83 (6/3) 99 99 7 5
10 178/109 (8/4) 146/99 (6/3) 76 73
11 149/87 (7/5) 108/73 (12/7) 70 61 2 2
12 123/76 (5/7) 94/58 (8/5) 119 115 4 4
13 145/91 (7/4) 115/78 (10/4) 87 88 8 3
14 160/85 (6/6) 117/71 (4/4) 111 119 4 3
141/89 (22/14) 113/75 (19/14) 95 (14) 93 (16) 6 (1.2) 5 (1.2)
P , 0.01 NS NS
Results are expressed as amean (sd) and bgeometric mean (antilog se)
immunoadsorbent assay (ELISA), intra-assay variation using paired design. Fisher’s exact test was used to evalu-
2.1%, and interassay variation 8.3% [13]. Residual urine ate proportions or dichothomans variables. All BP mea-
was determined by an ultrasonic diagnosis apparatus surements during the four-hour period were used to cal-
(Toshiba Sonolayergraph SAL-20A; Tokyo Shibaura culate the mean values and sd during each examination
Electric Co., Tokyo, Japan). Morning urine was tested in each patient. The differences between the two exami-
for bladder infection by a stix (Nephur-Test, Boehringer nation were transformed into relative changes, and linear
Mannheim, Germany). regression analysis was used to analyze for correlations.
All calculations were made using SPSS for Windows
Statistical analysis (SPSS Inc., Chicago, IL, USA). A P value of ,0.05 was
Normally distributed data are expressed as mean and considered significant (two tailed).
standard deviation (sd) or standard error of the mean
(se). Values for albuminuria were logarithmically trans-
RESULTSformed and expressed as geometric mean and antilog
The causes of albuminuria in the nondiabetic patientsse because of their positively skewed distribution. All
are shown in Table 1. The two groups were well matchedcomparisons of normally distributed parameters were
regarding age, sex, BP, and GFR (Tables 1 and 2).done with a Student’s t-test, and intergroup comparisons
were done with unpaired and intragroup comparisons Five (31%) patients with albuminuria and seven
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(50%) of the controls had a baseline BP . 140/90 mm
Hg (P 5 NS). In the group of patients with nondiabetic
nephropathies, three had previously received antihyper-
tensive treatment. No one in the control group had previ-
ous been treated with antihypertensive drugs. Intrave-
nous clonidine injection induced an equal and significant
reduction in MABP of 17 mm Hg and 19 mm Hg in
patients with nephropathy and control subjects, respec-
tively (P , 0.05; Table 2). MABP was reduced below
80 mm Hg in six (38%) of the patients with nephropathy
versus four (29%) in the controls (P 5 NS). The arterial
BP reduction for each patient is shown in Table 2.
Twelve out of 16 patients with nephropathy had a
reduction in GFR (mean difference 7.4 ml/min per 1.73
m2, P , 0.05) versus the control group, in which only 8
out of 14 patients had a reduction (mean difference of
1.3 ml/min per 1.73 m2, P 5 NS) after clonidine injection.
Seven of the patients with nephropathy had an abnormal
autoregulation of GFR, that is, a more than 10% reduc-
tion in relative GFR compared with only one in the
control group. The mean difference between changes in
GFR (95% confidence interval) between the nephro-
pathic and control subjects was 6.1 (4 0.03 to 12.2) ml/
min/1.73 m2 (P 5 0.051).
The reduction in GFR in the control group between
subjects with and without hypertension was alike. The
mean difference between changes in GFR was 1.7 (4 3.7
to 7.2) ml/min/1.73 m2 (P 5 NS).
We found no significant correlation between the rela-
tive change in mean arterial blood pressure (MABP; %)
and the relative change in GFR (%) in the patients with
albuminuria (Fig. 1). Three patients with nephropathy
had a nearly equal relative change in MABP and GFR
(Fig. 1), whereas none in the control group had a com-
plete pressure-passive vasculature. A significant correla-
tion between the relative reduction in MABP (%) and
the relative change in albuminuria (%) was demon-
strated in patients with nondiabetic nephropathies (r 5
0.55, P , 0.03).
A significant correlation between the relative change
in GFR (%) and baseline GFR was revealed in the group
of patients with nephropathy (r 5 0.55, P , 0.03). Fig. 1. Relative change in glomerular filtration rate (GFR; percentage
change of control GFR) and relative change in mean arterial bloodNo correlation was found between the autoregulation
pressure (MABP; percentage change of control MABP) induced byindex [relative change in GFR (%)/relative change in intravenous injection of clonidine. (A) Sixteen patients with nondiabetic
MABP (%)] and the duration of kidney disease (r 5 nephropathies (d) and their mean response (s). (B) Fourteen controls
(d) and their mean response (s).0.09, P 5 0.74) nor baseline albuminuria (r 5 0.41, P 5
0.17) in the albuminuric patients.
Eleven out of 16 patients with nondiabetic nephropa-
thy had a reduction in albuminuria (P , 0.05), and seven
DISCUSSIONof these patients also had a reduction in GFR.
Our randomized, single-blinded case-control studyThe relative change in GFR (%) did not correlate
shows that acute lowering of BP following an intravenouswith the relative change in albuminuria (%). Apart from
injection of clonidine reduces GFR and albuminuria ina dry mouth and sleepiness, no side-effects were ob-
served after clonidine injection. patients with different nondiabetic nephropathies. The
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changes in GFR induced by acute lowering of BP re-
vealed a wide variation in autoregulation capability rang-
ing from normal to severely impaired. A complete pres-
sure-passive vasculature was found in 3 out of 16
albuminuric patients [D MABP (%) 5 D GFR (%)],
whereas none of the control subjects revealed this phe-
nomenon. Our results suggest that the lower normal limit
of the autoregulation of the kidney in normoalbuminuric
nondiabetic human beings may be below the lower nor-
mal limit of autoregulation, that is, 80 mm Hg found in
animal studies [1, 14–17].
We used clonidine as a BP-lowering drug because
clonidine has no direct pharmacological effects on the
renal vessels [18–20] and no peripheral sympathetic inhi-
bition. Intravenous injection of clonidine in normoten-
sive and hypertensive subjects induces a slight but insig-
nificant reduction in peripheral and renal vein renin
concentration [18, 20]. The decrease in the BP is due to
diminished cardiac output, not to effects on total periph-
eral resistance [19, 20]. An intravenous injection of cloni-
dine (150 to 300 mg) to normotensive and hypertensive
nondiabetic subjects induces no significant change in re-
nal plasma flow and GFR [2, 18, 20]. The average reduc- Fig. 2. Reduction in mean arterial blood pressure (MABP) and glo-
merular filtration rate (GFR) induced by intravenous injection of cloni-tion in MABP ranges from 17 to 27 mm Hg in the three
dine in type 1 and type 2 diabetic patients with or without nephropathystudies mentioned earlier in this article. Because the and in nondiabetic (non-DM) subjects with or without nephropathy.
relative reduction in GFR did not exceed 10% of the
baseline value in any of these studies, this level was used
as a cutoff for normal GFR autoregulation.
We have used the plasma clearance of 51Cr-EDTA for pected taking into account the heterogenous causes of
proteinuria, its only partial dependence on glomerularGFR determination during the last 25 years because this
method is accurate, precise (coefficient of variation 4%), capillary hydraulic pressure (PGC), the rise in PGC when
systemic arterial BP drops below the autoregulatoryand does not require frequent timed urine collections
as do the classic renal clearance procedures [11, 12]. range [21], and the rather small number of patients inves-
tigated. Furthermore, the variation in the relative changeFurthermore, subjects receiving intravenous clonidine
cannot stand up and void within four to five hours after in MABP (%) between patients was rather narrow.
Experimental data indicate that when BP drops belowthe injection because of the orthostatic BP drop.
Originally, we reported defective GFR autoregulation the autoregulatory range, the efferent arteriole will con-
strict, thereby decreasing renal plasma flow and increas-in type 1 diabetic patients with diabetic nephropathy and
in hypertensive type 2 diabetic patients with or without ing glomerular capillary hydraulic pressure in order to
maintain GFR [21]. This compensatory phenomena maydiabetic nephropathy also applying clonidine as a BP-
lowering drug [2, 3]. In our prior studies of diabetic have contributed to the lack of correlation, as six of the
albuminuric patients (38%) had a reduction in MABPpatients with and without nephropathy and in this study,
an intravenous injection of (150 to 225 mg) clonidine to below 80 mm Hg.
The positive correlation between the relative changeinduced nearly the same reduction in average MABP in
all groups, ranging from 14 to 21 mm Hg (Fig. 2). This in GFR (%) and baseline GFR was unexpected, but
strongly depended on one patient, number 10, who hadreduction in MABP reduced significant GFR with 7 to
9 ml/min in patients with nephropathy, whereas no sig- a 20% increase in GFR despite an 18% lowering of
MABP (r 5 0.34, P 5 0.22). This correlation disappearednificant reduction in GFR was demonstrated in the nor-
moalbuminuric groups (Fig. 2). These results suggest if patient number 10 (this patient had an increase of 20%
in GFR) was excluded.that autoregulation is impaired in albuminuric patients
independent of the cause of albuminuria. The lack of The impaired myogenic responses to pressure changes
might be caused by arteriolar hyalinosis, which has beencorrelation between relative change in MABP (%) and
that in GFR and between the relative change in GFR seen in biopsy specimens from kidneys with hypertensive
lesions and/or diabetic glomerulosclerosis [22, 23]. Ex-(%) and that in albuminuria and between the autoregula-
tion index and baseline albuminuria is not entirely unex- perimental studies suggest that autoregulation of GFR
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is due to autoregulation of two of the main GFR determi- part explain the initial decline in GFR and the long-term
beneficial effect of aggressive antihypertensive treatmentnants, that is, renal plasma flow and glomerular capillary
pressure [1, 24]. The afferent arteriole plays a pivotal on albuminuria and the progression of diabetic and non-
diabetic nephropathies.role in regulating glomerular capillary pressure, renal
plasma flow, and, consequently, GFR [1, 25–29]. As the In conclusion, this study demonstrates that nondia-
betic patients with albuminuria often suffer from defec-ability of the afferent arteriole to dilate or constrict is a
critical component of the kidney’s defense against tive autoregulation of GFR, making the kidney unpro-
tected against changes in systemic BP.changes in renal perfusion pressure, a failure of the affer-
ent arteriole to constrict in the setting of elevated BP
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